News & Updates

When is the best time for kids to get flu vaccine?
When is the best time for kids to get flu vaccine?
16 Mar 2024 byStephen Padilla

Birth month is predictive of influenza vaccination timing in young children, owing to its impact on the scheduling of preventive care visits, reports a US study. Specifically, children born in October are more likely to be vaccinated in the same month and less likely to be diagnosed with influenza, supporting recommendations that promote October vaccination.

When is the best time for kids to get flu vaccine?
16 Mar 2024
Lockdown-induced inactivity may impair teens’ metabolic profile
Lockdown-induced inactivity may impair teens’ metabolic profile
15 Mar 2024

Forced sedentary behaviour, brought about by the COVID-19 lockdown, has negative effects on the metabolic and inflammatory profile of many teenagers, which can potentially lead to long-term poor health outcomes, suggests a study.

Lockdown-induced inactivity may impair teens’ metabolic profile
15 Mar 2024
Long COVID a driver of unemployment
Long COVID a driver of unemployment
14 Mar 2024 byAudrey Abella

Long COVID may have contributed to reduced participation in the UK labour market, a cohort study suggests.

Long COVID a driver of unemployment
14 Mar 2024
Is ART-free remission feasible in children born with HIV who received ART very early in life?
Is ART-free remission feasible in children born with HIV who received ART very early in life?
13 Mar 2024
Cefepime–taniborbactam bests meropenem for complicated UTI
Cefepime–taniborbactam bests meropenem for complicated UTI
10 Mar 2024 byJairia Dela Cruz

Patients with complicated urinary tract infection (UTI) may fare better with cefepime–taniborbactam than with meropenem, with the combination having been associated with much higher treatment success rates in the phase III CERTAIN-1 trial.

Cefepime–taniborbactam bests meropenem for complicated UTI
10 Mar 2024
Severe COVID-19 rare in PrEP-treated SARDs patients
Severe COVID-19 rare in PrEP-treated SARDs patients
08 Mar 2024 byStephen Padilla

Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.

Severe COVID-19 rare in PrEP-treated SARDs patients
08 Mar 2024